Hypera SA (HYPMY)
OTHER OTC:HYPMY
Want to see HYPMY full AI Analyst Report?
HYPMY Stock Chart & Stats
$4.31
$0.02(0.65%)
At close: 4:00 PM EST
$4.31
$0.02(0.65%)
Day’s Range― - ―
52-Week Range$3.39 - $5.19
Previous CloseN/A
Volume526.00
Average Volume (3M)110.00
Market Cap
$3.31B
Enterprise Value$24.34B
Total Cash (Recent Filing)$1.65B
Total Debt (Recent Filing)$9.34B
Price to Earnings (P/E)12.0
Beta0.70
Next Earnings
Apr 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.73%
Share Statistics
EPS (TTM)0.13
Shares Outstanding633,420,840
10 Day Avg. Volume0
30 Day Avg. Volume110
Financial Highlights & Ratios
PEG Ratio-1.11
Price to Book (P/B)1.15
Price to Sales (P/S)1.86
P/FCF Ratio8.08
Enterprise Value/Market Cap7.36
Enterprise Value/Revenue3.16
Enterprise Value/Gross Profit5.36
Enterprise Value/Ebitda10.77
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross And Net MarginsSustained gross (~58%) and net (~16%) margins indicate durable pricing power and effective cost control across manufacturing and commercial activities. High margins provide structural earnings resilience versus peers, supporting reinvestment and buffer against cyclical revenue swings over the next several months.
Revenue Returned To GrowthA return to roughly 10% TTM revenue growth suggests underlying demand recovery for core OTC and branded generics products in Brazil. Sustained top-line expansion supports scale economics, steadier cash flows, and the ability to leverage marketing and distribution spend for continued market-share gains.
Vertical Integration & Distribution ScaleVertical manufacturing and an extensive sales/distribution network provide durable competitive advantages: lower unit costs, faster inventory turns when managed well, and stronger control over supply. This structural setup supports margin sustainability and protects market share long term.
Bears Say
Weak Cash ConversionOperating cash generation lags earnings, pointing to working-capital drag or higher non-cash/recurring outflows. Subpar cash conversion limits financial flexibility for capex, acquisitions, or shareholder returns, and raises reliance on external funding if investments or margin pressures increase.
Profitability Moderated Vs Prior YearsEarnings have softened from peak years, implying either margin pressure or less efficient cost leverage. Lower trailing profitability reduces retained-earnings growth, constrains ROE expansion, and weakens the firm's ability to self-fund growth or absorb shocks without cutting investment or distributions.
Meaningful Leverage On Balance SheetLeverage near 0.76x equity leaves less balance-sheet cushion if operating performance weakens. With moderated profitability and cash conversion issues, debt levels could increase interest and refinancing risk, limiting strategic flexibility and elevating vulnerability to adverse industry or macro shocks.
Hypera SA News
HYPMY FAQ
What was Hypera SA’s price range in the past 12 months?
Hypera SA lowest stock price was $3.39 and its highest was $5.19 in the past 12 months.
What is Hypera SA’s market cap?
Hypera SA’s market cap is $3.31B.
When is Hypera SA’s upcoming earnings report date?
Hypera SA’s upcoming earnings report date is Apr 28, 2026 which is in 8 days.
How were Hypera SA’s earnings last quarter?
Hypera SA released its earnings results on Mar 12, 2026. The company reported $0.131 earnings per share for the quarter, beating the consensus estimate of N/A by $0.131.
Is Hypera SA overvalued?
According to Wall Street analysts Hypera SA’s price is currently Overvalued.
Does Hypera SA pay dividends?
Hypera SA pays a Notavailable dividend of $0.036 which represents an annual dividend yield of 4.73%. See more information on Hypera SA dividends here
What is Hypera SA’s EPS estimate?
Hypera SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hypera SA have?
Hypera SA has 633,420,840 shares outstanding.
What happened to Hypera SA’s price movement after its last earnings report?
Hypera SA reported an EPS of $0.131 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.059%.
Which hedge fund is a major shareholder of Hypera SA?
Currently, no hedge funds are holding shares in HYPMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hypera SA Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
43.89%
12-Months-Change
Fundamentals
Return on Equity
9.86%
Trailing 12-Months
Asset Growth
16.29%
Trailing 12-Months
Company Description
Hypera SA
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides dermo-cosmetics products under the Mantecorp Skincare brands; and consumer health products under the Apracur, Benegrip, Coristina d, Engov, Epocler, Estomazil, and other brands. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and similar and generic medicines under the Neo Química, Sodium Diclofenac, Hydroxyzine, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. is based in São Paulo, Brazil.
HYPMY Company Deck
HYPMY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements, including strong revenue growth, successful working capital optimization, and record operational cash flow. However, challenges were noted in the institutional market and R&D approval delays. Despite these challenges, the overall performance and strategic initiatives indicate a positive outlook.View all HYPMY earnings summariesTechnical Analysis
Perrigo Company
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Indivior
―
Amneal Pharmaceuticals
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
0.03% Other Institutional Investors
99.97% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---